Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s Nexium, GSK’s Zofran Among Latest Victims Of China Price Cuts; NDRC Plans Further Pricing Reforms To Encourage Innovation

This article was originally published in PharmAsia News

Executive Summary

China has announced another round of price cuts, this time targeting digestive drugs, which will impact AstraZeneca, GlaxoSmithKline and other MNCs.


Related Content

With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts